Four Decades for Justice
Cravath represented Mylan N.V. in connection with its US$6.5 billion 144A/Reg. S senior debt offering. Mylan N.V. is a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The transaction closed on June 9, 2016.
The Cravath team included partner William V. Fogg and associates Benjamin S. Persina, Daniel R. Satin, Martin P. Pepeljugoski and Jin‑Kyu Baek. Summer associate Dominic V. Capasso also worked on this matter.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.